Mineralys Therapeutics, Inc.
MLYS
$39.20
$0.050.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.66% | -2.52% | 13.76% | 13.13% | -37.37% |
| Total Depreciation and Amortization | -6.25% | 6.67% | 0.00% | 36.36% | 22.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.24% | -10.58% | 44.63% | 320.84% | 1,608.00% |
| Change in Net Operating Assets | -57.27% | 282.77% | 70.12% | -444.68% | -47.22% |
| Cash from Operations | 4.30% | 33.68% | 31.95% | -33.19% | -66.48% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -250.99% | 53.83% | -211.14% | 4.93% | 929.50% |
| Cash from Investing | -250.99% | 53.83% | -211.14% | 4.98% | 929.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,888.63% | -94.78% | 138,067.15% | 242.50% | -69.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 38.30% | -370.00% | 78.72% | -14.63% | 85.56% |
| Cash from Financing | 2,902.62% | -94.81% | 210,210.00% | 9,100.00% | 99.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 283.19% | -224.16% | 202.77% | -42.83% | 230.39% |